Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Expenses (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Accumulated Expenses data on record, last reported at $4.4 million in Q3 2022.

  • For Q3 2022, Accumulated Expenses rose 51.4% year-over-year to $4.4 million; the TTM value through Sep 2022 reached $4.4 million, up 51.4%, while the annual FY2021 figure was $4.2 million, 53.45% up from the prior year.
  • Accumulated Expenses reached $4.4 million in Q3 2022 per AVIR's latest filing, down from $10.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.5 million in Q2 2022 and bottomed at $824000.0 in Q1 2021.
  • Average Accumulated Expenses over 3 years is $4.0 million, with a median of $2.9 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: tumbled 54.21% in 2021, then skyrocketed 494.45% in 2022.
  • A 3-year view of Accumulated Expenses shows it stood at $2.7 million in 2020, then surged by 53.45% to $4.2 million in 2021, then increased by 4.42% to $4.4 million in 2022.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $4.4 million in Q3 2022, $10.5 million in Q2 2022, and $1.9 million in Q1 2022.